Treatment of MGMT promoter unmethylated glioblastoma with PD-1 inhibitor combined with anti-angiogenesis and epidermal growth factor receptor tyrosine kinase inhibitor: a case report

Glioblastoma (GBM) is the most common primary central nervous system (CNS) malignancy in adults and is associated with poor prognosis, especially even worse in those with unmethylated MGMT promoter. Currently, maximal safe resection combined with temozolomide (TMZ) concurrent chemoradiotherapy and T...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zheng, Du, Fangfang, Ren, Yi, Jiang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573431/
https://www.ncbi.nlm.nih.gov/pubmed/34805370
http://dx.doi.org/10.21037/atm-21-4625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573431/
https://www.ncbi.nlm.nih.gov/pubmed/34805370
http://dx.doi.org/10.21037/atm-21-4625

Ejemplares similares